AB-1002

DRUG2 trials

Sponsors

Askbio Inc., AskBio Inc

Conditions

Adult subjects with New York Heart Association (NYHA) Class III congestive heart failure and non-ischemic cardiomyopathyCongestive Heart Failure

Phase 2

Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure

Active, not recruitingNCT05598333

AskBio IncCongestive Heart Failure

Start: 2023-10-20End: 2030-12-31Target: 150Updated: 2025-12-03

(ASK-CHF2-CS201) A Phase 2, adaptive, double-blinded, placebo-controlled, randomized, multi-center trial to evaluate the efficacy, safety and tolerability of intracoronary infusion of AB-1002 in adult subjects with New York Heart Association (NYHA) Class III heart failure and non-ischemic cardiomyopathy

Active, not recruitingCTIS2024-510581-17-00

Askbio Inc.Adult subjects with New York Heart Association (NYHA) Class III congestive heart failure and non-ischemic cardiomyopathy

Start: 2024-11-05Target: 243Updated: 2025-12-16

Related Papers

GenePHIT phase 2 study design: a double blind, placebo-controlled trial to assess efficacy, safety, and tolerability of AB-1002 gene therapy in adults with heart failure

European Heart Journal2024-10-011 citations